银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2024年中国信创产业发展白皮书(完整版)
得益于中国数字经济的迅猛发展,2023年中国信创产业规模达20961.9亿元,2027年有望达到37011.3亿元,中国信创市场释放出前所未有的活力。艾媒咨询数据显示,2024年中国国产PC整机市场规模将达5182.3亿元,中国协同办公市场规模将达370.7亿元。信创基础消费潜力较大,尤其在办公软件领域,办公OA、编辑类的国产软件已普遍被企业应用,如企业微信、WPS等已积累了大量的用户群体。在国家信息安全驱动的需求下,信创产品及解决方案应用将在各行各业的渗透持续加深,行业规模持续增长。
白皮书由艾媒咨询主编,汇编芯片、服务器、整机等十五个信创重要行业数据信息。白皮书共计260页、68258个字、318个图表,内容丰富、数据详实,深入剖析了中国信创产业发展现状、产业链典型细分领域成长情况、标杆企业优秀经验以及未来发展趋势,为行业提供重要参考和决策依据。
Thanks to the rapid development of China's digital economy, the scale of China's credit creation industry will reach 2096.19 billion yuan in 2023, and is expected to reach 3701.13 billion yuan in 2027. China's credit creation market has released unprecedented vitality. Iimedia Consulting data show that in 2024, China's domestic PC machine market will reach 518.23 billion yuan, and China's collaborative office market will reach 37.07 billion yuan. Xinchuang basic consumption potential is large, especially in the field of office software, office OA, editing class of domestic software has been widely used by enterprises, such as enterprise wechat, WPS, etc., has accumulated a large number of users. Under the demand driven by national information security, the application of Xinchuang products and solutions will continue to deepen the penetration in all walks of life, and the industry scale will continue to grow.
The white paper is edited by IIMedia Consulting, compiling 15 important industry data information such as chips, servers, and complete machines. The white paper, with a total of 260 pages, 68,258 words and 318 charts, is rich in content and detailed in data, and thoroughly analyzes the development status quo of China's information and innovation industry, the growth of typical segments of the industrial chain, the excellent experience of benchmarking enterprises and the future development trend, providing important reference and decision-making basis for the industry. -
艾媒咨询|2021年中国医美机构市场竞争态势及企业营销模式分析报告
本报告研究涉及企业/品牌/案例:华韩整形,瑞丽医美,美莱整形,医思健康
数据显示,2016—2020年中国医美行业市场规模五年平均增长率为12.8%,与此同时,中国医美市场用户规模增长了4倍多。在人们生活水平的提升、年轻一代对医美的接受度的提高、政府监管层对医美行业的整治给医美消费者信心的提升的综合作用下,预计中国医美市场规模在2022年将达到2232亿元。随着医美产品及仪器技术水平提升、医美知识普及等,民众对整形美容的观念正在向积极态度转变,在整个行业扩张的过程中,轻医美的受众面广、门槛低、复购率高,更有可能提升市场整体渗透率,成为我国医美行业的主要增量市场。
According to the data, from 2016 to 2020, the five-year average growth rate of the market scale of China's medical and American industry was 12.8%. At the same time, the user scale of China's medical and American market increased by more than four times. Under the combined effect of the improvement of people's living standards, the improvement of the acceptance of medical beauty by the younger generation, the regulation of the medical beauty industry by the government regulators and the improvement of medical beauty consumer confidence, it is expected that the scale of China's medical beauty market will reach 223.2 billion yuan in 2022. With the improvement of the technical level of medical beauty products and instruments and the popularization of medical beauty knowledge, people's concept of plastic beauty is changing to a positive attitude. In the process of the expansion of the whole industry, light medical beauty has a wide audience, low threshold and high repurchase rate, which is more likely to improve the overall penetration rate of the market and become the main incremental market of China's medical beauty industry. -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00,国家卫生健康委员会公布全国确诊病例 11791 例,重症病例 1795 例。短期来看,预计疫情将继续持续一段时间。肺炎疫情期间,病毒检测带动试剂盒需求增加;病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:恒瑞医药,白云山,111集团,平安好医生,好大夫在线,优健康,春雨医生,微医,丁香医生,和美医疗,北大医疗,PHG,新氧,联合丽格,正广兴家庭医生,强森医疗,微脉,美中嘉和,零氪科技,中有精准医疗,思派网络,普瑞眼科,臻和科技,移宇科技,小鹿医馆,妈咪知道,八百方,京东医药,阿里健康大药房,1药网,一心堂,健一网,好药师,健客网,美丽神器,更美,悦美,美莱整形,伊美尔,丽都整形,芝星整形,欧华美科
大健康产业细分领域的垂直深化,推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响,2019年,大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示,受2018年和2019年上半年医疗领域负面舆情的影响,大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为,受社会医疗需求和国家政策的推动,大健康产业仍是未来投资的亮点。
The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2018-2019中国宠物食品产业研究与商业投资决策分析报告
本报告研究涉及企业/品牌包括:Thompson Street Capital Partner、Tropichem实验室、TetraGenx、Genoscoper、全球宠物用品控股公司GPP、荷兰国际投资公司ING、Schlotus、General Mills、Blue Buffalo、J.M.Smucker、Ainsworth Pet Nutrition、LLC(安斯沃思宠物营养品)公司、United Petfood、Animal Lovers、Nestle、Wamiz、Purina、荷兰IMCD、宠幸宠物、魔力猫盒、宠爱国际、疯狂的小狗、猫殿下、味及、宠安安、宠物之城、瑞派宠物、兴牧生物、宠爱堡、派迪畅科技、宇钛科技、云宠智能、爱宠医生、双安科技、皇家、比瑞吉、渴望、麦富迪、亚禾、顽皮、伊纳宝、伟嘉、喵趣、希宝、宝路、优卡、西莎、佳贝、冠能、康多乐、普瑞纳、妙多乐、喜跃、Wanpy、中宠、Kingdom PetS、Live、纯真肉本色、Dr Hao、脆脆香、Sea、Kingdom、KingKitty、Frisian、Mio9、佩蒂股份
iiMedia Research(艾媒咨询)数据显示,2018年中国养宠家庭超6000万,宠物饲养和饲养宠物家庭数量有明显增多。然而,在国外品牌具有明显优势的挑战下,中国宠物食品行业正面临跨越性发展以及生存双重压力,宠物食品企业还需在渠道、品质和品牌建设等方面投入发展。
As the data of iiMedia Research showed, the pet food industry reached 93.4 billion yuan in the market in 2018, with a growth rate of 86.8%. The growth rate is much higher than that of previous years. With the change of people's pet concept and the promotion of pet status, users are willing to spend more on pet food to protect the health and growth of pets. The overall situation of pet food industry is better.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告